论文部分内容阅读
目的观察厄贝沙坦与依那普利联合治疗2型糖尿病患者早期肾小球高滤过的疗效。方法2型糖尿病早期肾小球高滤过患者150例,随机分为常规治疗组(A组)和厄贝沙坦与依那普利联合治疗组(B组),共用药12周。测定2组治疗前后血压、尿白蛋白排泄率(UAER),应用WCP公式计算肾小球滤过率(GFR)。结果B组的UAER及GFR降低,与A组相比,差异有统计学意义(78.4±14.0)mg/24hvs(110.6±30.4)mg/24h,P<0.01;(138.5±30.0)ml/minvs(168.4±19.5)ml/min,P<0.01。结论厄贝沙坦与依那普利联合治疗可协同改善2型糖尿病患者早期肾小球高滤过状态,阻止和延缓糖尿病肾病的发生与发展。
Objective To observe the effect of irbesartan and enalapril in the treatment of early glomerular hyperfiltration in type 2 diabetic patients. Methods 150 type 2 diabetic patients with early glomerular hyperfiltration were randomly divided into routine treatment group (group A) and irbesartan and enalapril combined treatment group (group B) for 12 weeks. Blood pressure and urinary albumin excretion rate (UAER) were measured before and after treatment in two groups, and glomerular filtration rate (GFR) was calculated by WCP formula. Results The UAER and GFR in group B were significantly lower than those in group A (78.4 ± 14.0) mg / 24h vs (110.6 ± 30.4) mg / 24h, P <0.01; (138.5 ± 30.0) ml / min vs 168.4 ± 19.5) ml / min, P <0.01. Conclusion Combined treatment of irbesartan and enalapril can synergistically improve the state of early glomerular hyperfiltration in type 2 diabetic patients and prevent and delay the occurrence and development of diabetic nephropathy.